Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.10) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.21) EPS, FY2026 earnings at ($0.70) EPS and FY2027 earnings at ($0.04) EPS.

A number of other research firms have also commented on KPTI. Piper Sandler boosted their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Down 5.5 %

Shares of KPTI stock opened at $0.66 on Wednesday. The company has a market capitalization of $83.30 million, a P/E ratio of -0.58 and a beta of 0.07. Karyopharm Therapeutics has a 12-month low of $0.58 and a 12-month high of $1.95. The firm has a 50-day moving average price of $0.75 and a 200 day moving average price of $0.81.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the previous year, the business posted ($0.30) EPS. As a group, research analysts expect that Karyopharm Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd acquired a new stake in Karyopharm Therapeutics in the second quarter worth $31,000. Geode Capital Management LLC boosted its position in Karyopharm Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after purchasing an additional 43,856 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares in the last quarter. FMR LLC grew its stake in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $143,000. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).